Chronic suppurative otitis media (CSOM) is a widespread, debilitating problem with poorly understood immunology. Here, we assess the host response to middle ear infection over the course of a month post-infection in a mouse model of CSOM and in human subjects with the disease. Using multiparameter flow cytometry and a binomial generalized linear machine learning model, we identified Ly6G, a surface marker of mature neutrophils, as the most informative factor of host response driving disease in the CSOM mouse model. Consistent with this, neutrophils were the most abundant cell type in infected mice and Ly6G expression tracked with the course of infection. Moreover, neutrophil-specific immunomodulatory treatment using the neutrophil elastase inhibitor GW 311616A significantly reduces bacterial burden relative to ofloxacin-only treated animals in this model. The levels of dsDNA in middle ear effusion samples are elevated in both humans and mice with CSOM and decreased during treatment, suggesting that dsDNA may serve as a molecular biomarker of treatment response. Together these data strongly implicate neutrophils in the ineffective immune response to P. aeruginosa infection in CSOM and suggest that immunomodulatory strategies may benefit drug-tolerant infections for chronic biofilm-mediated disease.
Pseudomonas aeruginosa is a World Health Organization priority pathogen due to its ability to evolve resistance to all available antibiotics1. P. aeruginosa can cause a variety of biofilm-associated diseases including cystic fibrosis (CF) and chronic suppurative otitis media (CSOM), as well as implant-associated infections, and chronic cutaneous wound ulcers2,3,4,5,6,7.
Pseudomonal CSOM is the leading cause of permanent hearing loss in developing countries and accounts for the largest fraction of chronic Pseudomonal biofilm diseases, affecting over 300 million individuals worldwide8,9,10. Many patients eventually require surgery but relapse is still very common11,12. Traditional antimicrobial approaches fail to eradicate biofilms in CSOM and other settings due increased drug tolerance13,14. Fluoroquinolones remain the standard of care. However, efficacy is reduced in chronic infections compared to newly acquired infections, and rates of fluoroquinolone resistance are rising15.
Evolutionarily conserved defense mechanisms of bacteria include ways to subvert the host immune response—the role of neutrophils in biofilm-mediated diseases is an interesting topic of research in this regard, having both detrimental and protective roles in infection response16. Extracellular traps (NETs) are particularly interesting in cases of biofilm-mediated disease as NETs are primarily made of dsDNA (along with various cytosolic and granule proteins) and dsDNA is also a component of the extracellular biofilm matrix. There is evidence to suggest that necrotic neutrophils contribute DNA to the biofilm extracellular matrix as a result of failed attempts to clear infection17,18. Host biofilms are stronger and more developed in the host versus in a petri dish, and NETs can add to the integrity of the aggregate. It has previously been demonstrated in CSOM that neutrophil recruitment is increased to the infection site, and neutrophils in the middle ear promote bacterial biofilm stability through their contribution of dsDNA to the biofilm matrix19. These data support that induction of NETs elicited by biofilm contribute to the matrix of the bacterial aggregate and pinpoint the host immune response as a key factor in the chronicity of Pseudomonal bacterial infections.
Neutrophils may alter protein expression on bacterial cell walls and induce quorum signaling, further promoting conditions that support chronic infection and antibiotic tolerance20,21. Continuous recruitment of neutrophils to the site of infection may contribute to chronic infection through biofilm formation and inflammation that damages the host22. There is evidence that neutrophil elastase represses P. aeruginosa flagella expression and is selective for the non-motile biofilm phenotype23. Neutrophil elastase has been shown to contribute to disease pathogenesis and is a well-established marker of chronic bacterial infection; elastase presence is more damaging in chronic infection contrasting to acute infection24. Immunomodulation for treating other bacterial diseases has been successfully reported, providing the basis for a potential therapeutic solution25,26. Neutrophil immunomodulation has also been reported for other inflammation-mediated pathology such as atherosclerosis27. These lines of evidence suggest that adjunctive inhibition of elastase and other host-directed therapeutics might help counter the growing problem of ineffective antibiotics and promote clearance of P. aeruginosa biofilm infection. However, a potential role immunomodulation in the treatment of chronic middle ear bacterial disease, particularly CSOM, has not been explored.
Building off the foundation of many previously published animal models of acute and chronic otitis media that established microbial and host determinants of chronic infection28,29,30,31,32, we validated an animal model for CSOM33. In that model, we uncovered that chronic infection was dependent on dose, phenotype, and the proportion of P. aeruginosa persister cells, and demonstrated the ability of P. aeruginosa to form biofilm in vivo within 24 h33.
Here, using this model we investigated immunological changes that occur during the development of CSOM. We used machine learning to identify neutrophils as immunological drivers of P. aeruginosa CSOM in mice. Building on this result, we then tested the neutrophil elastase inhibitor GW 311616A in combination with ofloxacin as a potential adjuvant treatment regimen for P. aeruginosa CSOM. We further explored the potential of extracellular DNA as a biomarker for treatment response in CSOM and assessed the abundance of dsDNA in effusion from mice and human CSOM.
Alterations in myeloid infiltrate at the site of infection in response to middle ear biofilm infection
Chronic infection models provide the opportunity to explore changes in cell response both as the infection initially establishes within the host and as the disease becomes chronic. Here, using our recently described CSOM mouse model, we assessed the host response to middle ear infection over time by multiparameter flow cytometry (FCM) analysis.
To this end, we created tympanic membrane perforations and occluded Eustachian tubes in two groups of mice. One day later, half the mice received 1.6 × 107 CFU of P. aeruginosa PAO1 (PAO1.lux or PAO1.pUCP.eGFP) into the middle ear of C57Bl/6J mice via the ear canal. Control mice received an equal volume of sterile PBS. Bacterial density in the middle ear was measured by IVIS and by bacterial enumeration at the end of the experiment to confirm a chronic infection. We then collected 1–2 microliters of middle ear fluid from infected and control mice at 1, 14, and 28 days post-inoculation (d.p.i.) for FCM analysis.
Noticeable shifts in myeloid populations were observed (Fig. 1). Both minimal spanning tree (MST) plots and t-SNE observations were indicative of neutrophil expansion and subpopulations changing in Ly6G expression. Neutrophils initially expanded within 24 h in infected and control mice, likely due to injury-associated inflammation from model creation (Supplementary Fig. 1A, B). In uninfected control mice, by the 2-week time point contraction occurred. In contrast, in infected mice we found that neutrophils remained the most abundant population. We also observed changes in neutrophil subpopulations over the course of infection. Bacteria-infected specimens maintained significant neutrophil populations over time and in the infected mice markers of cell death were extensively noted throughout multiple subpopulations (Supplementary Fig. 1C, D).
Machine learning of infection response confirmed a potential immunomodulatory target
In order to improve interpretation of the FCM data, we used a machine learning approach. The FCM data were inserted into a binomial generalized linear model to computationally produce the maximum-likelihood target of infection status34.
Ly6G (Lymphocyte antigen complex 6 locus G6D), a specific surface marker of mature mouse neutrophils, was found to be a leading driver of infection in the middle ear 2 weeks post infection (Supplementary Fig. 2). The value of the coefficient of PE (−0.760013), including its p value (2e−16) and large absolute z value (−29.541) relative to other predictors, suggests a key role in influencing the infection status34. This information corroborated the subsets observed using t-SNE and MST, and further implicated a key role for neutrophils within the mouse model of CSOM.
Consistent with this role for neutrophils, in SEM imaging of mucosa from the middle ear we observed large numbers of neutrophils on middle ear mucosa of infected mice post infection. In contrast in the control animals, we identified a single putative neutrophil on otherwise normal appearing mucosa (Fig. 2). Together these data indicate that the response to infection in this model is associated with an abundance of neutrophils in both middle ear mucosa and effusion.
Alterations in neutrophil subsets and dsDNA at the site of infection in response to middle ear biofilm infection
Using our CSOM mouse model, we examined neutrophil numbers and maturity in more detail over time in samples collected on days 1, 14, and 28 d.p.i. (Fig. 3a). We observed that neutrophils became phenotypically altered in Ly6G expression, experiencing a significant reduction in the LyGhi subset by 14 d.p.i. (Fig. 3b). Next, we examined neutrophil subsets in the middle ear effusion of CSOM or control mice over time. Neutrophil subsets were manually gated based on Ly6G expression and CD11b+ CD45R− NK1.1− (Fig. 3c). Neutrophils remained the major cell type in effusion (>60%) post-inoculation. However, Ly6Gint (immature) neutrophils increased at the expense of the Ly6Ghi neutrophil subset in percent (approximately fivefold increase in Ly6Gint neutrophils, p < 0.05) and number (approximately fourfold increase in Ly6Gint neutrophils, p < 0.05) (Fig. 3d). These data demonstrate that with chronicity CSOM is associated with the accumulation of immature neutrophils in this model.
Given the abundance of neutrophils and the contribution of dead cells to extracellular DNA of bacterial biofilms17,18, we examined dsDNA levels resulting from CSOM infection in our model. We observed that dsDNA levels in CSOM were significantly greater compared to uninfected mice (mean of 4.5 ng/mL in uninfected control mice c.f. 32 ng/mL in CSOM mice, sevenfold change *p < 0.05) and increased over time (32–67 ng/mL, Supplementary Fig. 3). Together these data indicate that alterations in neutrophil subsets and dsDNA in middle ear effusion are associated with chronic biofilm infection of this model.
Efficacy of GW 311616A combined with ofloxacin in CSOM
The accumulation of an immature neutrophil population over time led us to investigate the role of neutrophils in treatment in this model. In conjunction with the fluoroquinolone antibiotic ofloxacin, the current standard of care for CSOM in humans, we treated mice with GW 311616A, a neutrophil elastase inhibitor and examined the impact of these regimens on bacterial load via IVIS and bacterial enumeration. A schematic of our protocol is provided in Fig. 4a.
Treatment with the neutrophil cytokine inhibitor GW 311616A plus ofloxacin led to non-detectable IVIS signal in mice treated with the immunomodulatory agent by the final day of treatment (day 14, Fig. 4b). A ~3-log reduction in bacterial burden was observed in excised homogenate of the infection site 3 days after treatment cessation (Fig. 4c). The PAO1 strain used in this study had a minimal inhibitory concentration (MIC) equal to 1.6 µg/ml for ofloxacin yet was unable to resolve chronic biofilm infection in vivo.
Using dsDNA as a biological marker of treatment, we likewise found the clinical response to GW 311616A combined with ofloxacin reduced levels of dsDNA to untreated (p > 0.05), bringing the response down to that of uninfected control levels. Treatment with ofloxacin alone (3 mg/ml) did not result in a significant difference between untreated mice (mean of 67 ng/mL in untreated c.f. mean of 25 ng/mL in ofloxacin only) (Fig. 4d). Together these data indicate that GW 311616A plus ofloxacin reduce bacterial burden and dsDNA in middle ear effusion in this model of Pseudomonal CSOM.
Levels of dsDNA are increased in human CSOM
Given these observations in the animal model, we postulated that human clinical specimens might also have observable dsDNA levels. We therefore collected middle ear fluid from non-CSOM ears (n = 4, including cochlear implant surgery and dry tympanic membrane perforation repair) and middle ear fluid from ears of patients with CSOM (n = 5).
We observed that middle ear fluid collected from CSOM patients (n = 5) had significantly increased dsDNA levels versus controls (range 6.3–42.5 ng/µL, *p < 0.05) (Fig. 5). In contrast, patients with conditions other than CSOM (control, n = 4) had dsDNA levels below the limit of detection. These data indicate that human CSOM is associated with elevated dsDNA levels in the middle ear and support the relevance of our animal model to human disease.
These results strongly implicate neutrophils in the ineffective immune response to P. aeruginosa infection observed in CSOM. We demonstrate increased numbers of neutrophils in a robust, recently described mouse model of CSOM as well as heightened dsDNA levels in human cases of the disease.
Moreover, our data indicate that it may be possible to target neutrophil elastase as an adjunctive treatment in CSOM. In functional studies in our newly established mouse model of CSOM, we demonstrated that treatment with neutrophil functional inhibitor potentiated ofloxacin treatment and resulted in a sustained reduction of bacterial burden greater than what is seen with ofloxacin alone. These data build on previous work of other biofilm infections that elastase-producing neutrophils at the site of infection may be contributing to the pathogenicity of P. aeruginosa. It is likely that elastase has additional function in promoting inflammation beyond tissue damage. In our model of CSOM, elastase inhibition potently synergizes with the antibiotic in clearance of the infection. It may engage both a direct effect on neutrophils and also collateral decrease in tissue inflammation. Interestingly, in a recent paper the authors found that elastase expression was the highest in immature neutrophils and is downregulated in mature neutrophils35. We found that CSOM is characterized by the shift in neutrophil phenotype to a more immature one. The mechanism of how exactly elastase inhibitor helps prevent the inflammation and infection is the subject of our further studies but we speculate that inhibiting elastase activity in immature neutrophils helps reduce DNA release and alters bacterial phenotype to render the bacterial cells more susceptible to antibiotic. Taken together, these data and our results encourage further studies of immunomodulatory agents against P. aeruginosa CSOM.
Bacteria find many ways to subvert host immunity to facilitate chronic infection. Indeed, multiple strategies from the bacteria to manipulate the host immune response have been reported36,37. Our study identified neutrophil Ly6G expression as an immunologic marker of CSOM infection. Ly6G is generally correlated with neutrophil differentiation and maturation and has been shown to be important for efficient anti-bacterial response38. Intriguingly, over the course of CSOM, Ly6G expression became very dim, meaning that over the course of infection, more immature neutrophils rather than mature neutrophils were recruited to the site. Bacterial infections can stimulate early neutrophil release from the bone marrow via CXCR4 signaling39. Similar phenotypic response is observed as part of emergency granulopoiesis in attempts to replace exhausted immune cells40. Importantly, phagocytosis and ROS production are higher in mature neutrophils and than immature ones, lending additional credence to the idea that rather than mounting an effective immune response these immature neutrophils may be feeding and protecting the biofilm, altering bacterial phenotype toward antibiotic tolerance35. Biofilm have taken advantage of the host immune response to facilitate survival in the hostile territory of the host and NET response in chronic infection is largely directed toward enhancing biofilm generation and bacterial phenotype alterations.
Our data support previous indications that dsDNA has value as a biomarker of CSOM treatment response41,42. There is great interest in identifying biomarkers for outcome prediction, especially in recurrent diseases in which assessment of a microbial cure remains limited43. The Food and Drug Administration has currently approved only eight biomarkers qualified for use in safety, diagnostic/prognostic, and monitoring of disease as part of the drug development process. We propose to use dsDNA as a biomarker to evaluate individual treatment response in the absence of a reproducible microbiological endpoint. This discovery allows infection status tracking via dsDNA quantitation from middle ear effusion.
We previously showed, in our animal model, that the conversion to inactive disease is likely temporary and this short term period is before recovery of the active disease. The Pseudomonas isolates used in this study are susceptible with MICs well within clinically relevant fluoroquinolone concentrations44. This supports that antibiotic resistance is not the reason for failure in our CSOM model. The likely mechanism, and likely underlying driving force in many recalcitrant infections such as CSOM, is the presence of persister cells within biofilm45. Persister cells maintain low metabolic activity and are less susceptible to antibiotic killing and their delayed growth resumption, allowing more time to recover from injury; further, after antibiotic cessation, persister cells resuscitate to become metabolically active. As persister cells are a likely candidate for recalcitrance in CSOM, a different choice of antibiotic, other than ofloxacin, is unlikely to improve overall efficacy.
Targeting the host immune system may serve as an effective adjunctive strategy for chronic infections caused by other antibiotic tolerant biofilm-associated pathogens. Particularly in diseases that allow for topical rather than systemic treatments, drug development of site-specific or topical immunosuppressant may be a more effective therapy as immediate mutational or stochastic bacterial responses are avoided. Consequently, site-specific inhibition of biofilm-associated neutrophils may represent a therapeutic route for treating chronic middle ear biofilm-associated infections. Therapeutic discovery combined with immunomodulation to permissive host features may provide an alternative approach toward disease eradication for other chronic biofilm infections. These data support the use of animal models of CSOM to identify targetable host mechanisms that can serve as potential drug target. While future discovery efforts are needed to further define the underlying pathogenesis in regard to immune-mediated infection maintenance, the methodology presented herein can be used to enhance early drug regime optimization for chronic biofilm infections.
All human samples were collected with approval from the Stanford School of Medicine Institutional Review Board. Human collection was procured with informed consent for middle ear fluid from patient’s undergoing surgery for CSOM or non-CSOM conditions (cochlear implant surgery and dry tympanic membrane perforation repair). Animal procedures were approved by the Institutional Animal Care and Use Committee at Stanford University. Mice (2–6 months old C57BL/6J male and female) were purchased from Jackson Laboratory or bred and housed in the Stanford University vivarium with ad libitum access to food and water. Mice with vestibular symptoms received subcutaneous injections of sterile saline weekly (Cat. No. 0409-4888-02, Hospira, Lake Forest, IL, USA). Experiments were performed independently at least twice with 3–5 animals per group.
Bacteria strains and preparation
P. aeruginosa PAO1 with constitutive expression of a chromosomal-encoded luminescence reporter (PAO1.lux) was constructed as previously described46. To create the fluorescent-tagged PAO1, a plasmid-encoded eGFP reporter (pUCP23.eGFP) was transformed into electrocompetent P. aeruginosa PAO1 (PAO1.pUCP23.eGFP) as previously described46. The expression of eGFP was confirmed via measurements at 478/510 nm. All organisms were cultured in LB broth from individual colonies at 37 °C, shaking at 200 RPM. Growth was monitored using a spectrophotometer at an optical density of 600 nm (OD600). For stationary cultures, bacteria were grown overnight and diluted to an OD of 0.8; the concentration used for inoculation (P. aeruginosa inoculum was 1.6 × 107 CFU).
We used a validated model of CSOM33,47. In brief, a sub-total tympanic membrane perforation and trans-tympanic Eustachian tube occlusion were performed 1 day prior to bacterial inoculation under anesthesia intraperitoneal injection of ketamine (65 mg/kg) and xylazine (5 mg/kg). The following day, model generation utilized direct inoculation of 10 µL bacterial inocula (1.6 × 107 CFU) of luminescent or fluorescent P. aeruginosa PAO1 (PAO1.lux or PAO1.pUCP.eGFP) into the middle ear of C57Bl/6J mice via the ear canal under anesthesia of intraperitoneal injection of ketamine (65 mg/kg) and xylazine (5 mg/kg) or 3% isoflurane. Control mice received an equal volume of sterile PBS. Bacterial density in the middle ear was measured by IVIS and by bacterial enumeration at the end of the experiment to confirm a chronic infection. Groups of mice were euthanized after 1,14, and 28 days after infection whereupon tissues and middle ear fluid were collected.
Real-time infection tracking
Disease progression was followed by capturing images with open emission using a LagoX In Vivo Imaging System (IVIS, Spectral Instruments Imaging, AZ, USA). Luminescence was quantified with the Aura software (Spectral Instruments Imaging, AZ, USA). Briefly, mice were placed on the right lateral position to expose the left ear at progressive days post-inoculation. Images were initially acquired at 60 s exposure with medium binning. If no signal was detected, mice were reanalyzed at 300 s exposure with high binning. Background luminescent signal was subtracted from signal coming from the area around the ear. Chronic infection was designated as the presence of infection 10 days post inoculation.
Antibiotics and immunomodulatory treatment
The neutrophil elastase inhibitor GW 311616A (2 mg/ml) (Axon Medchem, Groningen, Netherlands) was used in combination with 3% (3 mg/ml) ofloxacin Otic Solution (Apotex Corp, Weston, FL, USA) by dissolving in the antibiotic solution. Antibiotic or antibiotic-inhibitor combination (10 µL) were directly inoculated into the middle ear through an opened tympanic membrane wound generated as described in model generation. Antibiotic treatment alone or antibiotic with GW 311616A was performed twice daily for 2 weeks, allowing the mouse to lie on the ventral side for 5 min post treatment and then recover from anesthesia (2% isoflurane). Progression was monitored by IVIS as described above.
Broth microdilution for the minimum inhibitory concentration (MIC)
The MIC of the ofloxacin was determined against PAO1 using the broth microdilution method. The bacteria were grown overnight at 37 °C in LB medium. The drug was mixed with bacterial inoculum in LB (optical density OD at 600; OD600 = 0.2) and serial diluted (twofold) in 96-well polypropylene microplates. After overnight incubation, bacteria growth in the presence of the various drug concentrations was evaluated by visual observation of the solution (clear or cloudy) in the wells. The MIC was obtained from the lowest concentration of the drug, which show no bacterial growth.
Monoclonal antibodies, labeled with appropriate fluorochromes were purchased from BD Biosciences (San Jose, CA, USA), Invitrogen (Carlsbad, CA, USA), or Life Technologies (Carlsbad, CA USA). Cells isolated from the middle ear effusion were stained for Ly6G (clone 1A8), Ly6C (clone AL-21), NK1.1 (clone PK136), CD45R (B220 clone RA3-6B2), CD11c (clone HL3) (BD Biosciences, San Jose, CA, USA), CD11b (clone M1/70) (Invitrogen, Carlsbad, CA, USA), and live/dead markers, including nucleic acid Sytox dyes and amine-reactive dyes (Life Technologies, Carlsbad, CA USA). This allowed discrimination of neutrophil subsets based on staining of Ly6G: CD11b+ CD45R− NK1.1− Ly6Ghi mature cells; CD11b+ CD45R− NK1.1− Ly6Gint immature cells. Macrophages were identified as CD11b± CD45R− NK1.1− Ly6G− Ly6C+; and dendritic cells as CD11c+48. Cells undergoing phagocytosis were identified as positive for surface markers of subsets as above and also positive for the bacterial reporter GFP. Cells were analyzed on an LSRII flow cytometer (BD Biosciences, San Jose, CA, USA) and analysis was performed using FlowJo (BD Biosciences, San Jose, CA, USA). All samples were analyzed the same day as the samples were collected and cell identification by sequential gating performed on live cells with doublet discrimination.
Changes in myeloid infiltrate due to infection were visualized utilizing MST diagrams, a method used to assess how populations are related as well as determine the respective sizes of each population. We further screened subpopulation changes using t-SNE projections with FlowSOM clustering to visualize relation and abundance of subpopulations49,50,51. t-SNE maps are shown with a single color representing subpopulations (1–12) based on scatter and fluorescent intensity as measured by FCM. Region size is representative of increased cell density for the populations. Myeloid immunophenotype markers were also mapped by MST, with each point in the tree indicating single populations according to fluorescence intensity as measured by FCM. A plot is drawn in which each node is represented by a star chart indicating the median fluorescence intensities. Specifically, the tree plot shows median fluorescence intensity values of each protein marker. The FCM data were also inserted into a binomial generalized linear model to computationally discover the maximum-likelihood target of infection status34.
The site of infection in the middle ear was harvested to determine bacterial density. To determine bacteria burden via serial dilution, the tissues were homogenized in 1 mL sterile PBS and incubated for >2 h at 4 °C with shaking. Subsequently, the suspension was diluted and drop plated on LB agar for bacterial enumeration. Replicates were performed within the countable range with every sample. The limit of detection is 102 CFU/mL.
Nucleic acid quantitation in murine CSOM
The AccuBlue Broad Range dsDNA Quantitation Kit (Cat. No. 31007, Biotium, Fremont, CA, USA) was used to detect dsDNA in each of the samples. Samples were blind-tested, and the concentration of dsDNA was calculated from the fluorescence readings of a microplate reader. Each plate contained middle ear effusion samples, dsDNA standards provided by the quantitation kit, a water control, and a PBS control. Sample were assessed in duplicate. Water and PBS controls served to correct from the background interference readings on the microplate reader.
This kit was used to quantify dsDNA in mouse samples at various time points after infection. Control mice and mice day 3 and day 7 post infection were used to compare the progression of the disease. The 3D control group had a sterile effusion sample collected at the same time as the infected sample. dsDNA concentration was calculated from microplate fluorescence readings.
Nucleic acid quantitation in human CSOM
Informed consent was obtained from all human participants. Human samples of middle ear effusion of patients undergoing surgery for CSOM and conditions unrelated to bacterial infections were collected and stored in liquid nitrogen until analysis. Using the AccuBlue Broad Range dsDNA Quantitation Kit (Cat. No. 31007, Biotium, Fremont, CA USA) as above, positive samples were matched with patients with known CSOM infections, while the negative samples were matched the patients with no infection (e.g., cochlea implant surgery negative controls). Analysts were double-blinded to the status of the patient.
Scanning electron microscopy and sample processing
Middle ear samples were fixed in 2% glutaraldehyde/4% formaldehyde in sodium cacodylate buffer (pH 7.3) for 24 h at room temperature and then stored at 4 °C. 1% OsO4 was added followed by sequential ethanol washes of 50%, 70%, 95%, and 100%. To remove the ethanol and dry the sample, HMDS was used and then allowed to air dry. The Critical Point Dryer (CPD) was used to remove the remaining ethanol. Sample was then attached to a 12 mm stub using double stick, carbon-conductive tape and coated with gold/paladium (Au/Pd) at a 60:40 ratio. Using a FEI Strata 235DB dual-beam scanning electron microscopy (FIB-SEM), images of P. aeruginosa infected middle ear mucosa were taken.
Analysis was performed using GraphPad Prism 7.0 or 8.0 (GraphPad Software, Inc., La Jolla, CA) to test statistical significance. P values were calculated using either unpaired t-test; or one-way ANOVA with Tukey–Kramer test. P values <0.05 were considered significant.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
All data needed to evaluate the conclusions in the paper are present in the paper. Additional data related to this paper may be requested from the corresponding author.
Tacconelli, E. & Magrini, N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 1–7 (World Health Organization, 2019).
Hassett, D. J. et al. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends Microbiol. 17, 130–138 (2009).
Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318–1322 (1999).
Hoiby, N., Ciofu, O. & Bjarnsholt, T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 5, 1663–1674 (2010).
Lam, J., Chan, R., Lam, K. & Costerton, J. W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect. Immun. 28, 546–556 (1980).
Zimmerli, W. & Moser, C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol. Med. Microbiol. 65, 158–168 (2012).
Maji, P. K., Chatterjee, T. K., Chatterjee, S., Chakrabarty, J. & Mukhopadhyay, B. B. The investigation of bacteriology of chronic suppurative otitis media in patients attending a tertiary care hospital with special emphasis on seasonal variation. Indian J. Otolaryngol. Head Neck Surg. 59, 128–131 (2007).
Gu, X., Keyoumu, Y., Long, L. & Zhang, H. Detection of bacterial biofilms in different types of chronic otitis media. Eur. Arch. Otorhinolaryngol. 271, 2877–2883 (2014).
Saunders, J., Murray, M. & Alleman, A. Biofilms in chronic suppurative otitis media and cholesteatoma: scanning electron microscopy findings. Am. J. Otolaryngol. 32, 32–37 (2011).
Acuin, J. Chronic suppurative otitis media: burden of Illness and management options. 1–83 (World Health Organization, 2004).
Fishman, I. et al. Demographics and microbiology of otorrhea through patent tubes failing ototopical and/or oral antibiotic therapy. Otolaryngol. Head Neck Surg. 145, 1025–1029 (2011).
Stagg, H. R. et al. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. Eur. Respir. J. 54, 1900982 (2019).
Verderosa, A., Totsika, M. & Fairfull-Smith, K. Bacterial biofilm eradication agents: a current review. Front. Chem. 7, 824 (2019).
Yang, L. et al. Combating biofilms. FEMS Immunol. Med. Microbiol. 65, 146–157 (2011).
Pachori, P., Gothalwal, R. & Gandhi, P. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis. 6, 109–119 (2019).
Berends, E. T. et al. Nuclease expression by Staphylococcus aureus facilitates escape from neutrophil extracellular traps. J. Innate Immun. 2, 576–586 (2010).
Walker, T. S. et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect. Immun. 73, 3693–3701 (2005).
Alhede, M. et al. The origin of extracellular DNA in bacterial biofilm infections in vivo. Path. Dis. 78, ftaa018 (2020).
Thornton, R. B. et al. Neutrophil extracellular traps and bacterial biofilms in middle ear effusion of children with recurrent acute otitis media —a potential treatment target. PLoS ONE 8, e53837 (2013).
Koomer, A., Quinn, T., Bamberger, D. & Herndon, B. L. Neutrophil antimicrobial interaction in the established infection: effect on Staphylococcus aureus. J. Infect. 52, 320–328 (2006).
Caceres, S. M. et al. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob. Agents Chemother. 58, 6851–6860 (2014).
Hirschfeld, J. Dynamic interactions of neutrophils and biofilms. J. Oral Microbiol. 6, 26102 (2014).
Sonawane, A., Jyot, J., During, R. & Ramphal, R. Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa. Infect. Immun. 74, 6682–6689 (2006).
Domon, H. et al. Neutrophil elastase subverts the immune response by cleaving toll-like receptors and cytokines in pneumococcal pneumonia. Front. Immunol. 9, 732 (2018).
Pott, G., Beard, K., Bryan, C., Merrick, D. & Shapiro, L. Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells. Front. Public Health 1, 19 (2013).
Woods, D., Cantin, A., Cooley, J., Kenney, D. & Remold-O’Donnell, E. Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Pediatr. Pulmonol. 39, 141–149 (2005).
Wen, G. et al. Genetic and pharmacologic inhibition of the neutrophil elastase inhibits experimental atherosclerosis. J. Am. Heart Assoc. 7, e008187 (2018).
Schachern, P. A. et al. Effect of lipooligosaccharide mutations of Haemophilus influenzae on the middle and inner ears. Int J. Pediatr. Otorhinolaryngol. 73, 1757–1760 (2009).
Piltcher, O. B. et al. A rat model of otitis media with effusion caused by eustachian tube obstruction with and without Streptococcus pneumoniae infection: methods and disease course. Otolaryngol. Head Neck Surg. 126, 490–498 (2002).
Aynali, G. et al. The effects of methylprednisolone, montelukast and indomethacine in experimental otitis media with effusion. Int J. Pediatr. Otorhinolaryngol. 75, 15–19 (2011).
Huang, Q. et al. Hypoxia-inducible factor and vascular endothelial growth factor pathway for the study of hypoxia in a new model of otitis media with effusion. Audio. Neurootol. 17, 349–356 (2012).
Tuoheti, A., Gu, X., Cheng, X. & Zhang, H. Silencing Nrf2 attenuates chronic suppurative otitis media by inhibiting pro-inflammatory cytokine secretion through up-regulating TLR4. Innate Immun. 24, 1753425920933661 (2020).
Khomtchouk, K. et al. A novel mouse model of Chronic Suppurative Otitis Media and its use in preclinical antibiotic evaluation. Sci. Adv. 6, eabc1828 (2020).
Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636–645 (2015).
Evrard, M. et al. Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions. Immunity 48, 364–379 (2018).
Donlan, R. M. & Costerton, J. W. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15, 167–193 (2002).
González, J. F., Hahn, M. M. & Gunn, J. S. Chronic biofilm-based infections: skewing of the immune response. Path. Dis. 76, fty023 (2018).
Deniset, J. F., Surewaard, B. G., Lee, W. Y. & Kubes, P. Splenic Ly6Ghigh mature and Ly6Gint immature neutrophils contribute to eradication of S. pneumoniae. J. Exp. Med. 214, 1333–1350 (2017).
Eash, K. J., Means, J. M., White, D. W. & Link, D. C. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood 113, 4711–4719 (2009).
Sánchez, Á. et al. Map3k8 controls granulocyte colony-stimulating factor production and neutrophil precursor proliferation in lipopolysaccharide-induced emergency granulopoiesis. Sci. Rep. 7, 5010 (2017).
Bhattacharya, M. et al. Staphylococcus aureus biofilms release leukocidins to elicit extracellular trap formation and evade neutrophil-mediated killing. PNAS 115, 7416–7421 (2018).
Parks, Q. M. et al. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J. Med. Microbiol. 58, 492–502 (2009).
Hall‐Stoodley, L. & Stoodley, P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol. 1, 7–10 (2005).
Ohyama, M. et al. Ofloxacin otic solution in patients with otitis media: an analysis of drug concentrations. Arch. Otolaryngol. Head Neck Surg. 125, 337–340 (1999).
Spoering, A. L. & Lewis, K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J. Bacteriol. 183, 6746–6751 (2001).
Pletzer, D., Mansour, S. C., Wuerth, K., Rahanjam, N., Hancock, R. E. W. New mouse model for chronic infections by Gram-negative bacteria enabling the study of anti-infective efficacy and host-microbe interactions. 8, e00140-17 (2017).
Varsak, Y. & Santa Maria, P. Mouse model of experimental Eustachian tube occlusion: a surgical technique. Acta Oto-Laryngol. 136, 12–17 (2016).
Rose, S., Misharin, A. & Perlman, H. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry 81, 343–350 (2012).
Chester, C. & Maecker, H. T. Algorithmic tools for high-dimensional cytometry data. J. Immunol. 195, 773–779 (2015).
Lugli, E., Roederer, M. & Cossarizza, A. Data analysis in flow cytometry: the future just started. Cytometry 77A, 705–713 (2010).
Saeys, Y., Van Gassen, S. & Lambrecht, B. Computational flow cytometry: helping to make sense of high-dimensional immunology data. Nat. Rev. Immunol. 16, 449–462 (2016).
Special thanks to Dr. Lisa Nichols and Meredith Weglarz at Stanford Shared FACS Facility for supporting flow cytometry analysis and to John Perrino of Stanford University Cell Science Imaging Facility for SEM preparation. We would like to thank the Department of Otolaryngology for funding this study through startup funds for PSM. Our thanks for core support from the Stanford Initiative to Cure Hearing Loss through generous gifts from the Bill and Susan Oberndorf Foundation. This work was also supported by grants NIH LRP from NCATS to K.M.K., Stanford MCHRI through SPARK to K.M.K., A.X., and P.S.M., Stanford Bio-X USRP to L.I.J. and P.S.M., and seed funding to P.S.M. from Action on Hearing Loss. The use of scanning electron microscope was performed at the Stanford Nano Shared Facilities (SNSF) and supported by the National Science Foundation under award ECCS-1542152 and an SNSF Mini Seed Grant to S.M. Data were collected with analyzers at the Stanford Shared FACS Facility (SSFF) obtained using NIH S10 Shared Instrument Grant (S10RR027431-01).
K.M.K., P.L.B., D.P., and P.S.M. are inventors on patent applications for novel drugs against P. aeruginosa (nos. 15/219,073; 62/027721; 62/027698; 63/024,963; and 62/873,717). The rest of the authors declare that there are no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Khomtchouk, K.M., Joseph, L.I., Khomtchouk, B.B. et al. Treatment with a neutrophil elastase inhibitor and ofloxacin reduces P. aeruginosa burden in a mouse model of chronic suppurative otitis media. npj Biofilms Microbiomes 7, 31 (2021). https://doi.org/10.1038/s41522-021-00200-z
Journal of Neuroinflammation (2022)